GF Fund Management’s Entrada Therapeutics TRDA Stock Holding History

GF Fund Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.61K	Buy	884 +72	+9%	+$499	﹤0.01%	571
2026 Q2	$5.98K	Sell	812 -40	-5%	-$384	﹤0.01%	564
2026 Q1	$10.8K	Buy	852 +101	+13%	+$1.16K	﹤0.01%	554
2025 Q4	$7.72K	Sell	751 -56	-7%	-$472	﹤0.01%	600
2025 Q3	$4.68K	Sell	807 -151	-16%	-$883	﹤0.01%	611
2025 Q2	$6.44K	Hold	958	–	–	﹤0.01%	611
2025 Q1	$8.66K	Buy	958 +173	+22%	+$2.16K	﹤0.01%	582
2024 Q4	$13.6K	Buy	+785	New	+$14.2K	﹤0.01%	508

Other funds holding TRDA

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GF Fund Management's TRDA Position: Q3 2026 in Review

GF Fund Management increased its Entrada Therapeutics (TRDA) stake by 8.9% in Q3 2026, buying an estimated $499 and bringing the position to 884 shares worth $5.61K. The position accounts for ﹤0.01% of the portfolio, ranked #571.

GF Fund Management first reported a position in TRDA in Q4 2024 and has held it in 8 quarters since. The position peaked at $13.6K in Q4 2024. 23 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

GF Fund Management held 884 shares of Entrada Therapeutics worth $5.61K as of Q3 2026.
GF Fund Management bought 72 Entrada Therapeutics shares in Q3 2026, an estimated $499.
Entrada Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #571 holding.
GF Fund Management first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 8 quarters since.
GF Fund Management's Entrada Therapeutics position peaked at $13.6K in Q4 2024.
23 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.